EVMN (Evommune, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by EVMN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | Kyle Carver | Chief Financial Officer | Buy | — | — |
| 2026-07-08 | ARTHUR S KIRSCH | Director | Buy | — | — |
| 2026-06-24 | Luis C. Pena | President & CEO | Sell | — | — |
| 2026-06-24 | Jeegar Pravinkumar Patel | Chief Scientific Officer | MIXED | — | — |
| 2026-06-24 | Janice Suzann Drew | Chief of Dev. Operations | MIXED | — | — |
| 2026-06-03 | ARTHUR S KIRSCH | Director | A | — | — |
| 2026-06-03 | Jeegar Pravinkumar Patel | Chief Scientific Officer | MIXED | — | — |
| 2026-06-03 | Luis C. Pena | President & CEO | Sell | — | — |
| 2026-06-03 | David E Cohen | Director | Sell | — | — |
| 2026-06-03 | BENJAMIN F MCGRAW III | Director | A | — | — |
| 2026-06-01 | Kyle Carver | Chief Financial Officer | MIXED | — | — |
| 2026-06-01 | Gregory S. Moss | Chief Business & Legal Officer | MIXED | — | — |
| 2026-04-17 | Janice Suzann Drew | Chief of Dev. Operations | A | — | — |
| 2026-04-17 | Luis C. Pena | President & CEO | A | — | — |
| 2026-04-17 | Eugene Bauer | Chief Medical Officer | A | — | — |
| 2026-04-17 | Gregory S. Moss | Chief Business & Legal Officer | A | — | — |
| 2026-04-17 | Jeegar Pravinkumar Patel | Chief Scientific Officer | A | — | — |
| 2026-04-17 | Kyle Carver | Chief Financial Officer | A | — | — |
| 2026-02-19 | 7 Cooperative UA LSP | Director | A | — | — |
| 2026-02-18 | Weegen Felice Isabel Verduyn-van | Director | A | — | — |
| 2026-02-17 | RA Capital Nexus Fund III, L.P. | Director | A | — | — |
| 2025-12-22 | Robert Lorne Hopfner | Director | Buy | — | — |
| 2025-12-19 | Eugene Bauer | Chief Medical Officer | A | — | — |
| 2025-12-11 | Jeegar Pravinkumar Patel | Chief Scientific Officer | F | — | — |
| 2025-12-11 | Janice Suzann Drew | EVP, Operations | F | — | — |
| 2025-12-11 | Gregory S. Moss | Chief Business & Legal Officer | F | — | — |
| 2025-12-11 | Luis C. Pena | President & CEO | F | — | — |
| 2025-12-11 | Kyle Carver | Chief Financial Officer | F | — | — |
| 2025-12-11 | Eugene Bauer | Chief Medical Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 5,288,313 | — |
| — | Director | 5,288,313 | — |
| — | Director | 2,710,293 | — |
| — | President & CEO | 630,458 | — |
| — | Director | 294,502 | — |
| — | Chief Medical Officer | 270,818 | — |
| — | Chief of Dev. Operations | 87,794 | — |
| — | Chief Business & Legal Officer | 64,010 | — |
| — | Chief Financial Officer | 60,335 | — |
| — | Chief Scientific Officer | 46,403 | — |
| — | Director | 18,209 | — |
| — | Director | 10,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EVMN quote page; the site-wide leaderboard is on the insider transactions hub.